AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN Form_NN 20-F_JJ Information_NN 2004_CD 147_CD Shareholder_NN Information_NN AstraZeneca_NNP 2000 2001 2002 2003_CD 2004_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN year_NN end_NN 1,766_CD 1,745_CD 1,719_CD 1,693_CD 1,645_CD Weighted_VBN average_NN for_IN year_NN 1,768_CD 1,758_CD 1,733_CD 1,709_CD 1,673_CD Stock_NN market_NN price_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP Highest_NNP pence_NN 3600 3555 3625 2868_CD 2749_CD Lowest_NNP pence_NN 1926 2880 1799 1820_CD 1863_CD At_IN year_NN end_NN pence_NN 3375 3098 2220 2680_CD 1889_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 1.62_CD $_$ 1.73_CD $_$ 1.84_CD $_$ 1.78_CD $_$ 2.11_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP basic_JJ $_$ 1.30_CD $_$ 1.65_CD $_$ 1.64_CD $_$ 1.78_CD $_$ 2.28_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP diluted_VBD $_$ 1.30_CD $_$ 1.65_CD $_$ 1.64_CD $_$ 1.78_CD $_$ 2.28_CD Dividends_NNPS $_$ 0.70_CD $_$ 0.70_CD $_$ 0.70_CD $_$ 0.795_CD $_$ 0.94_CD In_IN addition_NN ,_, shareholders_NNS received_VBD a_DT distribution_NN of_IN shares_NNS in_IN Syngenta_NNP AG_NNP as_IN a_DT dividend_NN in_IN specie_NN in_IN respect_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS ._.
Percentage_NN analysis_NN at_IN 31_CD December_NNP 2004_CD of_IN issued_VBN share_NN capital_NN By_IN size_NN of_IN account_NN 2004_CD No._NN ._.
In_IN addition_NN ,_, there_EX were_VBD approximately_RB 45,000_CD holders_NNS of_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS representing_VBG 8.82_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN and_CC 161,000_CD holders_NNS of_IN shares_NNS held_VBN under_IN the_DT VPC_NNP Services_NNPS Agreement_NNP representing_VBG 22.63_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN ._.
The_DT ADRs_NNPS ,_, each_DT of_IN which_WDT is_VBZ equivalent_JJ to_TO one_CD Ordinary_NNP Share_NN ,_, are_VBP issued_VBN by_IN JPMorgan_NNP Chase_NNP Bank_NNP ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN 148_CD Form_NN 20-F_JJ Information_NN 2004_CD Shareholder_NN Information_NN continued_VBD AstraZeneca_NNP PLC_NNP Since_IN April_NNP 1999_CD ,_, following_VBG the_DT AstraZeneca_NNP merger_NN ,_, the_DT principal_JJ markets_NNS for_IN trading_NN in_IN the_DT shares_NNS of_IN AstraZeneca_NNP PLC_NNP are_VBP the_DT London_NNP ,_, Stockholm_NNP and_CC New_NNP York_NNP Stock_NNP Exchanges_NNPS ._.
The_DT table_NN below_IN sets_NNS forth_RB ,_, for_IN the_DT four_CD quarters_NNS of_IN 2003_CD and_CC for_IN the_DT first_JJ two_CD quarters_NNS and_CC last_JJ six_CD months_NNS of_IN 2004_CD the_DT reported_VBN high_JJ and_CC low_JJ share_NN prices_NNS of_IN AstraZeneca_NNP PLC_NNP ,_, on_IN the_DT following_VBG bases_NNS :_: for_IN shares_NNS listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP LSE_NNP the_DT reported_VBN high_JJ and_CC low_JJ middle_JJ market_NN closing_VBG quotations_NNS are_VBP derived_VBN from_IN The_DT Daily_NNP Official_NNP List_NN :_: for_IN shares_NNS listed_VBN on_IN the_DT Stockholm_NNP Stock_NNP Exchange_NNP SSE_NNP the_DT high_JJ and_CC low_JJ closing_NN sales_NNS prices_NNS are_VBP as_IN stated_VBN in_IN the_DT Official_NNP List_NN :_: for_IN American_JJ Depositary_NNP Shares_NNP ADS_NNPS listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP the_DT reported_VBN high_JJ and_CC low_JJ sales_NNS prices_NNS are_VBP as_IN reported_VBN by_IN Dow_NNP Jones_NNP ADR_NNP quotations_NNS ._.
The_DT average_JJ price_NN paid_VBN per_IN share_NN in_IN 2004_CD was_VBD 2376_CD pence_NN ._.
Between_IN 1999_CD and_CC 2003_CD a_DT total_NN of_IN 92.8_CD million_CD Ordinary_NNP Shares_NNP were_VBD re-purchased_JJ ,_, and_CC subsequently_RB canceled_VBN ,_, at_IN an_DT average_JJ price_NN of_IN 2762_CD pence_NN per_IN share_NN for_IN a_DT consideration_NN ,_, including_VBG expenses_NNS ,_, of_IN $_$ 3,959_CD m._FW The_DT excess_NN of_IN the_DT consideration_NN over_IN the_DT nominal_JJ value_NN was_VBD charged_VBN against_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN ._.
Shares_NNP issued_VBD in_IN respect_NN of_IN share_NN schemes_NNS totalled_VBD 2.5_CD million_CD ._.
In_IN 1999_CD ,_, in_IN connection_NN with_IN the_DT merger_NN ,_, AstraZenecas_NNP share_NN capital_NN was_VBD redenominated_VBN in_IN US_NNP dollars_NNS ._.
On_IN 6_CD April_NNP 1999_CD ,_, Zeneca_NNP shares_NNS were_VBD canceled_VBN and_CC US_NNP dollar_NN shares_NNS issued_VBN ,_, credited_VBN as_IN fully_RB paid_VBN on_IN the_DT basis_NN of_IN one_CD dollar_NN share_NN for_IN each_DT Zeneca_NNP share_NN then_RB held_VBD ._.
This_DT was_VBD achieved_VBN by_IN a_DT reduction_NN of_IN capital_NN under_IN section_NN 135_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Upon_IN the_DT reduction_NN of_IN capital_NN becoming_VBG effective_JJ ,_, all_DT issued_VBN and_CC unissued_VBN Zeneca_NNP shares_NNS were_VBD canceled_VBN and_CC the_DT sum_NN arising_VBG as_IN a_DT result_NN thereof_RB credited_VBD to_TO a_DT special_JJ reserve_NN which_WDT was_VBD converted_VBN into_IN US_NNP dollars_NNS at_IN the_DT rate_NN of_IN exchange_NN prevailing_VBG on_IN the_DT record_NN date_NN ._.
This_DT US_NNP dollar_NN reserve_NN was_VBD then_RB applied_VBN in_IN paying_VBG up_RP ,_, at_IN par_NN ,_, newly_RB created_VBN US_NNP dollar_NN shares_NNS ._.
At_IN the_DT same_JJ time_NN as_IN the_DT US_NNP dollar_NN shares_NNS were_VBD issued_VBN ,_, the_DT Company_NN issued_VBN 50,000_CD Redeemable_JJ Preference_NN Shares_NNS with_IN a_DT nominal_JJ value_NN of_IN 1.00_CD each_DT for_IN cash_NN at_IN par_NN ._.
The_DT Redeemable_JJ Preference_NN Shares_NNS carry_VBP limited_JJ class_NN voting_NN rights_NNS and_CC no_DT dividend_NN rights_NNS ._.
This_DT class_NN of_IN shares_NNS is_VBZ also_RB capable_JJ of_IN redemption_NN at_IN par_NN at_IN the_DT option_NN of_IN the_DT Company_NN on_IN the_DT giving_VBG of_IN seven_CD days_NNS written_VBN notice_NN to_TO the_DT registered_VBN holder_NN of_IN the_DT shares_NNS ._.
A_DT total_NN of_IN 826_CD million_CD AstraZeneca_NNP shares_NNS were_VBD issued_VBN to_TO Astra_NNP shareholders_NNS who_WP accepted_VBD the_DT merger_NN offer_NN before_IN the_DT final_JJ closing_NN date_NN ,_, 21_CD May_NNP 1999_CD ._.
AstraZeneca_NNP received_VBD acceptances_NNS from_IN Astra_NNP shareholders_NNS representing_VBG 99.6_CD per_IN cent_NN of_IN Astras_NNP shares_NNS and_CC the_DT remaining_VBG 0.4_CD per_IN cent_NN was_VBD acquired_VBN in_IN 2000_CD for_IN cash_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN Form_NN 20-F_JJ Information_NN 2004_CD 149_CD Major_JJ shareholdings_NNS On_IN 26_CD January_NNP 2005_CD the_DT following_NN had_VBD disclosed_VBN an_DT interest_NN in_IN the_DT issued_VBN Ordinary_NNP Share_NNP capital_NN of_IN the_DT Company_NN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN Sections_NNS 198-208_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD :_: Date_NN of_IN Percentage_NN disclosure_NN of_IN issued_VBN Shareholder_NN Number_NN of_IN shares_NNS to_TO Company_NNP share_NN capital_NN The_DT Capital_NNP Group_NNP Companies_NNS ,_, Inc._NNP 220,352,313_CD 26_CD Jan_NNP 2005_CD 13.39_CD %_NN Investor_NN AB_NNP 63,465,810_CD 11_CD Feb_NNP 2004_CD 3.86_CD %_NN Wellington_NNP Management_NNP Co._NNP ._.
LLP_NNP 53,510,141_CD 28_CD Jul_NNP 2004_CD 3.25_CD %_NN Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP 52,518,020_CD 13_CD Jun_NN 2002_CD 3.19_CD %_NN Barclays_NNP PLC_NNP 50,634,731_CD 1_CD Oct_NNP 2004_CD 3.08_CD %_NN No_DT other_JJ person_NN held_VBD a_DT notifiable_JJ interest_NN in_IN shares_NNS ,_, comprising_VBG 3_CD %_NN or_CC more_JJR of_IN the_DT issued_VBN Ordinary_NNP Share_NNP capital_NN of_IN the_DT Company_NN ,_, appearing_VBG in_IN the_DT register_NN of_IN interests_NNS in_IN shares_NNS maintained_VBN under_IN the_DT provisions_NNS of_IN Section_NN 211_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Since_IN the_DT date_NN of_IN disclosure_NN to_TO the_DT Company_NN ,_, the_DT interest_NN of_IN any_DT person_NN listed_VBN above_IN in_IN the_DT Ordinary_NNP Shares_NNP of_IN the_DT Company_NN may_MD have_VB increased_VBN or_CC decreased_VBN ._.
No_DT requirement_NN to_TO notify_VB the_DT Company_NN of_IN any_DT increase_NN or_CC decrease_NN would_MD have_VB arisen_VBN unless_IN the_DT holding_VBG moved_VBD up_RP or_CC down_RP through_IN a_DT whole_JJ number_NN percentage_NN level_NN ._.
The_DT percentage_NN level_NN may_MD increase_VB on_IN the_DT cancellation_NN of_IN shares_NNS following_VBG a_DT re-purchase_NN of_IN shares_NNS under_IN the_DT Companys_NNP share_NN re-purchase_JJ program_NN or_CC decrease_NN on_IN the_DT issue_NN of_IN new_JJ shares_NNS under_IN any_DT of_IN the_DT Companys_NNPS share_NN plans_NNS ._.
Changes_NNS in_IN the_DT percentage_NN ownership_NN held_VBN by_IN major_JJ shareholders_NNS during_IN the_DT past_JJ three_CD years_NNS are_VBP set_VBN out_RP below_IN ._.
Major_JJ shareholders_NNS do_VBP not_RB have_VB different_JJ voting_NN rights_NNS ._.
Percentage_NN of_IN issued_VBN share_NN capital_NN Shareholder_NN 26_CD Jan_NNP 2005_CD 28_CD Jan_NNP 2004_CD 29_CD Jan_NNP 2003_CD 17_CD Feb_NNP 2002_CD The_DT Capital_NNP Group_NNP Companies_NNS ,_, Inc._NNP 13.39_CD %_NN 15.01_CD %_NN 11.92_CD %_NN 11.09_CD %_NN Investor_NN AB_NNP 3.86_CD %_NN 5.41_CD %_NN 5.33_CD %_NN 5.25_CD %_NN Wellington_NNP Management_NNP Co._NNP ._.
LLP_NNP 3.25_CD %_NN 3.00_CD %_NN 3.00_CD %_NN 3.00_CD %_NN Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP 3.19_CD %_NN 3.10_CD %_NN 3.06_CD %_NN 3.00_CD %_NN Barclays_NNP PLC_NNP 3.08_CD %_NN 3.00_CD %_NN 3.00_CD %_NN 3.00_CD %_NN AstraZeneca_NNP PLC_NNP American_NNP Depositary_NNP Shares_NNP each_DT representing_VBG one_CD Ordinary_NNP Share_NNP evidenced_VBD by_IN American_JJ Depositary_NNP Receipts_NNPS issued_VBN by_IN JPMorgan_NNP Chase_NNP Bank_NNP ,_, as_IN depositary_JJ ,_, are_VBP listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
As_IN of_IN 26_CD January_NNP 2005_CD ,_, the_DT proportion_NN of_IN Ordinary_NNP Shares_NNP represented_VBN by_IN American_JJ Depositary_NNP Shares_NNP was_VBD 8.77_CD %_NN of_IN the_DT Ordinary_NNP Shares_NNP outstanding_JJ ._.
Number_NN of_IN registered_VBN holders_NNS of_IN Ordinary_NNP Shares_NNP as_IN of_IN 26_CD January_NNP 2005_CD :_: In_IN the_DT US_NNP 823_CD Total_JJ 160,672_CD Number_NN of_IN record_NN holders_NNS of_IN American_JJ Depositary_NNP Receipts_NNPS as_IN of_IN 26_CD January_NNP 2005_CD :_: In_IN the_DT US_NNP 2,877_CD Total_JJ 2,907_CD So_RB far_RB as_IN the_DT Company_NN is_VBZ aware_JJ ,_, it_PRP is_VBZ neither_DT directly_RB nor_CC indirectly_RB owned_VBN nor_CC controlled_VBN by_IN one_CD or_CC more_JJR corporations_NNS or_CC by_IN any_DT government_NN ._.
As_IN of_IN 26_CD January_NNP 2005_CD ,_, the_DT total_JJ amount_NN of_IN the_DT Companys_NNP voting_NN securities_NNS owned_VBN by_IN Directors_NNS and_CC Officers_NNS of_IN the_DT Company_NN was_VBD :_: Amount_NNP owned_VBD Title_NN of_IN class_NN $_$ 0.25_CD shares_NNS Percent_NN of_IN class_NN Ordinary_NNP Shares_NNP 394,632_CD 0.02_CD %_NN The_DT Company_NN does_VBZ not_RB know_VB of_IN any_DT arrangements_NNS ,_, the_DT operation_NN of_IN which_WDT might_MD result_VB in_IN a_DT change_NN in_IN the_DT control_NN of_IN the_DT Company_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN 150_CD Form_NN 20-F_JJ Information_NN 2004_CD Shareholder_NN Information_NN continued_VBD Related_JJ party_NN transactions_NNS During_IN the_DT period_NN 1_CD January_NNP 2005_CD to_TO 26_CD January_NNP 2005_CD ,_, there_EX were_VBD no_DT transactions_NNS ,_, loans_NNS ,_, or_CC proposed_VBN transactions_NNS between_IN the_DT Company_NN and_CC any_DT related_JJ parties_NNS which_WDT were_VBD material_NN to_TO either_CC the_DT Company_NN or_CC the_DT related_JJ party_NN ,_, or_CC which_WDT were_VBD unusual_JJ in_IN their_PRP$ nature_NN or_CC conditions_NNS ._.
Options_NNS to_TO purchase_VB securities_NNS from_IN registrant_JJ or_CC subsidiaries_NNS a_DT At_IN 26_CD January_NNP 2005_CD ,_, options_NNS outstanding_JJ to_TO subscribe_VB for_IN Ordinary_NNP Shares_NNP of_IN $_$ 0.25_CD of_IN the_DT Company_NN were_VBD :_: Number_NN of_IN shares_NNS Subscription_NNP price_NN Normal_JJ expiry_NN date_NN 55,518,810_CD 891p3487p_CD 20052014_CD The_DT weighted_JJ average_JJ subscription_NN price_NN of_IN options_NNS outstanding_JJ at_IN 26_CD January_NNP 2005_CD was_VBD 2714p_JJ ._.
All_DT options_NNS were_VBD granted_VBN under_IN Company_NN employee_NN schemes_NNS ._.
b_NN Included_VBN in_IN paragraph_NN a_DT are_VBP options_NNS granted_VBN to_TO Directors_NNS and_CC Officers_NNS of_IN AstraZeneca_NNP as_IN follows_VBZ :_: Number_NN of_IN shares_NNS Subscription_NNP price_NN Normal_JJ expiry_NN date_NN 2,253,693_CD 891p3487p_CD 20052014_CD c_NN Included_VBN in_IN paragraph_NN b_NN are_VBP options_NNS granted_VBN to_TO individually_RB named_VBN Directors_NNS ._.
Details_NNS of_IN these_DT option_NN holdings_NNS at_IN 31_CD December_NNP 2004_CD are_VBP shown_VBN in_IN the_DT Directors_NNS Remuneration_NNP Report_NNP ._.
During_IN the_DT period_NN 1_CD January_NNP 2005_CD to_TO 26_CD January_NNP 2005_CD ,_, no_DT Director_NNP exercised_VBN any_DT options_NNS ._.
On_IN 14_CD January_NNP 2005_CD ,_, Hkan_NNP Mogren_NNP ceased_VBD to_TO have_VB an_DT interest_NN in_IN an_DT option_NN over_IN 6,462_CD Ordinary_NNP Shares_NNP on_IN the_DT expiry_NN of_IN the_DT option_NN ._.
Dividend_NN payments_NNS The_DT record_NN date_NN for_IN the_DT second_JJ interim_JJ dividend_NN for_IN 2004_CD ,_, payable_JJ on_IN 21_CD March_NNP 2005_CD in_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP ,_, is_VBZ 11_CD February_NNP 2005_CD ._.
Shares_NNP trade_NN ex-dividend_NN on_IN the_DT London_NNP and_CC Stockholm_NNP Stock_NNP Exchanges_NNPS from_IN 9_CD February_NNP 2005_CD and_CC ADRs_NNPS trade_NN ex-dividend_NN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP from_IN the_DT same_JJ date_NN ._.
From_IN 2005_CD ,_, dividends_NNS will_MD normally_RB be_VB paid_VBN as_IN follows_VBZ :_: First_NNP interim_JJ :_: Announced_JJ end_NN of_IN July_NNP and_CC paid_VBN in_IN September_NNP ._.
Second_JJ interim_NN :_: Announced_JJ end_NN of_IN January_NNP and_CC paid_VBN in_IN March_NNP ._.
The_DT record_NN date_NN for_IN the_DT first_JJ interim_JJ dividend_NN for_IN 2005_CD ,_, payable_JJ on_IN 19_CD September_NNP 2005_CD in_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP ,_, is_VBZ 12_CD August_NNP 2005_CD ._.
Shareview_NNP AstraZenecas_NNP shareholders_NNS with_IN internet_NN access_NN may_MD visit_VB shareview_NN ._.
co._FW uk_FW and_CC register_VB their_PRP$ details_NNS to_TO create_VB a_DT portfolio_NN ._.
Shareview_NNP is_VBZ a_DT free_JJ and_CC secure_JJ on-line_JJ service_NN from_IN Lloyds_NNP TSB_NNP Registrars_NNPS that_WDT gives_VBZ access_NN to_TO shareholdings_NNS including_VBG balance_NN movements_NNS ,_, indicative_JJ share_NN prices_NNS and_CC information_NN about_IN recent_JJ dividends_NNS ._.
ShareGift_NNP AstraZeneca_NNP welcomes_VBZ and_CC values_VBZ all_DT its_PRP$ shareholders_NNS ,_, no_DT matter_NN how_WRB many_JJ or_CC how_WRB few_JJ shares_NNS they_PRP own_VBP ._.
However_RB ,_, shareholders_NNS who_WP have_VBP only_RB a_DT small_JJ number_NN of_IN shares_NNS whose_WP$ value_NN makes_VBZ it_PRP uneconomic_JJ to_TO sell_VB them_PRP ,_, either_RB now_RB or_CC at_IN some_DT stage_NN in_IN the_DT future_NN ,_, may_MD wish_VB to_TO consider_VB donating_VBG them_PRP to_TO charity_NN through_IN ShareGift_NNP ,_, an_DT independent_JJ charity_NN share_NN donation_NN scheme_NN ._.
One_CD feature_NN of_IN the_DT scheme_NN is_VBZ that_IN there_EX is_VBZ no_DT gain_NN or_CC loss_NN for_IN capital_NN gains_NNS tax_NN purposes_NNS on_IN gifts_NNS of_IN shares_NNS through_IN ShareGift_NNP and_CC it_PRP may_MD now_RB also_RB be_VB possible_JJ to_TO obtain_VB income_NN tax_NN relief_NN on_IN the_DT donation_NN ._.
Further_JJ information_NN about_IN ShareGift_NNP can_MD be_VB found_VBN on_IN its_PRP$ website_NN ,_, sharegift_NN ._.
org_NN ,_, or_CC by_IN contacting_VBG ShareGift_NNP on_IN 020 7337 0501_CD or_CC at_IN 46_CD Grosvenor_NNP Street_NNP ,_, London_NNP W1K_NNP 3HN_NNP ._.
More_JJR information_NN about_IN the_DT tax_NN position_NN on_IN gifts_NNS of_IN shares_NNS to_TO ShareGift_NNP can_MD be_VB obtained_VBN from_IN the_DT Inland_NNP Revenue_NN whose_WP$ website_JJ address_NN is_VBZ inlandrevenue_JJ ._.
The_DT share_NN transfer_NN form_NN needed_VBN to_TO make_VB a_DT donation_NN may_MD be_VB obtained_VBN from_IN the_DT AstraZeneca_NNP Registrar_NNP ,_, Lloyds_NNP TSB_NNP Registrars_NNPS whose_WP$ address_NN can_MD be_VB found_VBN on_IN the_DT back_JJ cover_NN of_IN this_DT document_NN ._.
ShareGift_NNP is_VBZ administered_VBN by_IN The_DT Orr_NNP Mackintosh_NNP Foundation_NNP ,_, registered_VBD charity_NN number_NN 1052686_CD ._.
The_DT Unclaimed_NNP Assets_NNPS Register_NNP AstraZeneca_NNP supplies_VBZ unclaimed_JJ dividend_NN data_NNS to_TO the_DT Unclaimed_NNP Assets_NNPS Register_NNP UAR_NNP which_WDT provides_VBZ investors_NNS who_WP have_VBP lost_VBN track_NN of_IN shareholdings_NNS with_IN an_DT opportunity_NN to_TO search_VB the_DT UARs_NNS database_NN of_IN unclaimed_JJ financial_JJ assets_NNS on_IN payment_NN of_IN a_DT small_JJ ,_, fixed_JJ fee_NN ._.
The_DT UAR_NNP donates_VBZ part_NN of_IN the_DT search_NN fee_NN to_TO charity_NN ._.
The_DT UAR_NNP can_MD be_VB contacted_VBN at_IN Leconfield_NNP House_NNP ,_, Curzon_NNP Street_NNP ,_, London_NNP W1J_NNP 5JA_NNP and_CC at_IN uar_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN Form_NN 20-F_JJ Information_NN 2004_CD 151_CD Results_NNS Unaudited_JJ trading_NN results_NNS of_IN AstraZeneca_NNP in_IN respect_NN of_IN the_DT first_JJ three_CD months_NNS of_IN 2005_CD will_MD be_VB published_VBN on_IN 28_CD April_NNP 2005_CD and_CC results_NNS in_IN respect_NN of_IN the_DT first_JJ six_CD months_NNS of_IN 2005_CD will_MD be_VB published_VBN on_IN 28_CD July_NNP 2005_CD ._.
Documents_NNS on_IN display_NN The_DT Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP of_IN the_DT Company_NN and_CC other_JJ documents_NNS concerning_VBG the_DT Company_NN which_WDT are_VBP referred_VBN to_TO in_IN this_DT document_NN may_MD be_VB inspected_VBN at_IN the_DT Companys_NNPS registered_VBD office_NN at_IN 15_CD Stanhope_NNP Gate_NNP ,_, London_NNP W1K_NNP 1LN_NNP ._.
Taxation_NNP for_IN US_NNP residents_NNS The_DT following_JJ summary_NN of_IN the_DT material_NN UK_NNP and_CC certain_JJ US_NNP tax_NN consequences_NNS of_IN ownership_NN of_IN Ordinary_NNP Shares_NNP or_CC ADRs_NNPS held_VBD as_IN capital_NN assets_NNS by_IN US_NNP resident_NN shareholders_NNS is_VBZ based_VBN on_IN current_JJ UK_NNP and_CC US_NNP federal_JJ income_NN tax_NN law_NN ,_, including_VBG the_DT new_JJ US_NNP UK_NNP double_JJ taxation_NN convention_NN relating_VBG to_TO income_NN and_CC capital_NN gains_NNS ,_, which_WDT entered_VBD into_IN force_NN on_IN 31_CD March_NNP 2003_CD the_DT Convention_NNP and_CC the_DT prior_JJ US_NNP UK_NNP double_JJ taxation_NN convention_NN relating_VBG to_TO income_NN and_CC capital_NN gains_NNS the_DT Prior_RB Convention_NNP ,_, and_CC practice_NN ._.
This_DT discussion_NN is_VBZ also_RB based_VBN in_IN part_NN on_IN representations_NNS of_IN JPMorgan_NNP Chase_NNP Bank_NNP as_IN Depositary_NNP for_IN ADRs_NNPS and_CC assumes_VBZ that_IN each_DT obligation_NN in_IN the_DT deposit_NN agreement_NN among_IN the_DT Company_NN ,_, the_DT Depositary_NNP and_CC the_DT holders_NNS from_IN time_NN to_TO time_NN of_IN ADRs_NNPS and_CC any_DT related_JJ agreements_NNS will_MD be_VB performed_VBN in_IN accordance_NN with_IN their_PRP$ terms_NNS ._.
The_DT US_NNP Treasury_NNP has_VBZ expressed_VBN concerns_NNS that_IN parties_NNS to_TO whom_WP ADRs_NNPS are_VBP pre-released_JJ may_MD be_VB taking_VBG actions_NNS that_WDT are_VBP inconsistent_JJ with_IN the_DT claiming_VBG ,_, by_IN US_NNP holders_NNS of_IN ADRs_NNS ,_, of_IN foreign_JJ tax_NN credits_NNS for_IN US_NNP federal_JJ income_NN tax_NN purposes_NNS ._.
Such_JJ actions_NNS could_MD also_RB be_VB inconsistent_JJ with_IN the_DT claiming_VBG of_IN the_DT reduced_JJ tax_NN rate_NN ,_, described_VBN below_IN ,_, applicable_JJ to_TO dividends_NNS received_VBN by_IN certain_JJ non-corporate_JJ US_NNP resident_NN shareholders_NNS ._.
Accordingly_RB ,_, the_DT analysis_NN of_IN the_DT creditability_NN of_IN UK_NNP taxes_NNS and_CC the_DT availability_NN of_IN the_DT reduced_JJ tax_NN rate_NN for_IN dividends_NNS received_VBN by_IN certain_JJ non-corporate_JJ US_NNP resident_NN shareholders_NNS both_CC as_IN described_VBN below_IN ,_, could_MD be_VB affected_VBN by_IN future_JJ actions_NNS that_WDT may_MD be_VB taken_VBN by_IN parties_NNS to_TO whom_WP ADRs_NNPS are_VBP pre-released_JJ ._.
UK_NNP and_CC US_NNP income_NN taxes_NNS and_CC tax_NN treaties_NNS affecting_VBG remittance_NN of_IN dividends_NNS Under_IN the_DT Prior_RB Convention_NNP ,_, US_NNP resident_NN individuals_NNS who_WP were_VBD the_DT beneficial_JJ owners_NNS of_IN dividends_NNS on_IN Ordinary_NNP Shares_NNP ,_, or_CC ADRs_NNS representing_VBG Ordinary_NNP Shares_NNP ,_, in_IN UK_NNP corporations_NNS were_VBD generally_RB entitled_VBN to_TO a_DT tax_NN credit_NN payment_NN in_IN respect_NN of_IN dividends_NNS equal_JJ to_TO one-ninth_JJ 1_CD 9th_CD of_IN the_DT dividend_NN paid_VBD the_DT Tax_NNP Credit_NNP Amount_NNP ._.
This_DT tax_NN credit_NN payment_NN was_VBD reduced_VBN by_IN a_DT UK_NNP withholding_VBG the_DT UK_NNP withholding_NN of_IN up_RB to_TO 15_CD %_NN of_IN the_DT gross_JJ dividend_NN paid_VBN ._.
Therefore_RB ,_, a_DT US_NNP holder_NN would_MD not_RB actually_RB receive_VB any_DT payment_NN of_IN this_DT credit_NN ._.
US_NNP resident_JJ corporate_JJ shareholders_NNS are_VBP generally_RB treated_VBN in_IN the_DT same_JJ way_NN as_IN individuals_NNS provided_VBD that_DT either_CC alone_RB ,_, or_CC together_RB with_IN associated_VBN corporations_NNS ,_, they_PRP do_VBP not_RB control_VB directly_RB or_CC indirectly_RB 10_CD %_NN or_CC more_JJR of_IN the_DT voting_NN shares_NNS of_IN the_DT Company_NN and_CC do_VB not_RB constitute_VB investment_NN or_CC holding_VBG companies_NNS ,_, 25_CD %_NN or_CC more_JJR of_IN the_DT capital_NN of_IN which_WDT is_VBZ owned_VBN ,_, directly_RB or_CC indirectly_RB ,_, by_IN persons_NNS that_WDT are_VBP not_RB individuals_NNS resident_NN in_IN ,_, and_CC are_VBP not_RB nationals_NNS of_IN ,_, the_DT US_NNP ._.
Under_IN the_DT Convention_NNP ,_, US_NNP resident_NN shareholders_NNS are_VBP no_RB longer_RB entitled_VBN to_TO the_DT Tax_NNP Credit_NNP Amount_NNP because_IN the_DT Convention_NNP does_VBZ not_RB provide_VB for_IN that_DT entitlement_NN ._.
The_DT Convention_NNP applies_VBZ to_TO dividend_NN payments_NNS after_IN 1_CD May_NNP 2003_CD ._.
However_RB ,_, if_IN a_DT US_NNP resident_NN shareholder_NN would_MD have_VB been_VBN entitled_VBN to_TO greater_JJR benefits_NNS under_IN the_DT Prior_RB Convention_NNP ,_, the_DT US_NNP resident_NN shareholder_NN may_MD elect_VB to_TO continue_VB to_TO apply_VB the_DT Prior_RB Convention_NNP until_IN 1_CD May_NNP 2004_CD ._.
For_IN US_NNP federal_JJ income_NN tax_NN purposes_NNS ,_, the_DT dividend_NN paid_VBN and_CC ,_, if_IN a_DT US_NNP resident_NN shareholder_NN elects_VBZ under_IN the_DT Prior_RB Convention_NNP to_TO claim_VB a_DT foreign_JJ tax_NN credit_NN with_IN respect_NN to_TO the_DT UK_NNP withholding_NN ,_, the_DT associated_VBN Tax_NNP Credit_NNP Amount_NNP are_VBP includible_JJ in_IN gross_JJ income_NN by_IN US_NNP resident_NN shareholders_NNS and_CC ,_, for_IN foreign_JJ tax_NN credit_NN limitation_NN purposes_NNS ,_, are_VBP foreign_JJ source_NN income_NN ._.
The_DT UK_NNP withholding_NN is_VBZ treated_VBN as_IN a_DT foreign_JJ income_NN tax_NN which_WDT may_MD ,_, subject_JJ to_TO certain_JJ limitations_NNS and_CC restrictions_NNS ,_, be_VB eligible_JJ for_IN credit_NN against_IN a_DT US_NNP resident_NN shareholders_NNS US_PRP federal_JJ income_NN tax_NN liability_NN or_CC deductible_JJ by_IN such_JJ shareholders_NNS in_IN computing_VBG their_PRP$ taxable_JJ income_NN for_IN a_DT US_NNP resident_NN shareholder_NN who_WP elects_VBZ to_TO include_VB the_DT associated_VBN Tax_NNP Credit_NNP Amount_NNP in_IN income_NN ._.
Subject_JJ to_TO applicable_JJ limitations_NNS ,_, dividends_NNS received_VBN by_IN certain_JJ US_NNP resident_NN non-corporate_JJ holders_NNS of_IN Ordinary_NNP Shares_NNP or_CC ADRs_NNPS in_IN taxable_JJ years_NNS beginning_VBG before_IN 1_CD January_NNP 2009_CD may_MD be_VB subject_JJ to_TO US_NNP federal_JJ income_NN tax_NN at_IN a_DT maximum_NN rate_NN of_IN 15_CD %_NN ._.
US_NNP resident_NN shareholders_NNS should_MD consult_VB their_PRP$ own_JJ tax_NN advisors_NNS to_TO determine_VB whether_IN they_PRP are_VBP subject_JJ to_TO any_DT special_JJ rules_NNS which_WDT may_MD not_RB limit_VB their_PRP$ ability_NN to_TO be_VB taxed_VBN at_IN this_DT favourable_JJ rate_NN ._.
Taxation_NNP on_IN capital_NN gains_NNS Under_IN the_DT Convention_NNP each_DT contracting_NN state_NN may_MD in_IN general_JJ tax_NN capital_NN gains_NNS in_IN accordance_NN with_IN the_DT provisions_NNS of_IN its_PRP$ domestic_JJ law_NN ._.
Under_IN present_JJ UK_NNP law_NN ,_, individuals_NNS who_WP are_VBP neither_DT resident_NN nor_CC ordinarily_RB resident_NN in_IN the_DT UK_NNP ,_, and_CC companies_NNS which_WDT are_VBP not_RB resident_JJ in_IN the_DT UK_NNP will_MD not_RB be_VB liable_JJ to_TO UK_NNP tax_NN on_IN capital_NN gains_NNS made_VBN on_IN the_DT disposal_NN of_IN their_PRP$ Ordinary_NNP Shares_NNP or_CC ADRs_NNPS ,_, unless_IN such_JJ Ordinary_NNP Shares_NNP or_CC ADRs_NNPS are_VBP held_VBN in_IN connection_NN with_IN a_DT trade_NN ,_, profession_NN or_CC vocation_NN carried_VBD on_IN in_IN the_DT UK_NNP through_IN a_DT branch_NN or_CC agency_NN ._.
A_DT US_NNP resident_NN shareholder_NN will_MD recognize_VB capital_NN gain_NN or_CC loss_NN for_IN US_NNP federal_JJ income_NN tax_NN purposes_NNS on_IN the_DT sale_NN or_CC exchange_NN of_IN Ordinary_NNP Shares_NNP or_CC ADRs_NNPS in_IN the_DT same_JJ manner_NN as_IN such_JJ a_DT holder_NN would_MD on_IN the_DT sale_NN or_CC exchange_NN of_IN any_DT other_JJ shares_NNS held_VBD as_IN capital_NN assets_NNS ._.
As_IN a_DT result_NN ,_, a_DT US_NNP resident_NN shareholder_NN will_MD generally_RB recognize_VB capital_NN gain_NN or_CC loss_NN for_IN US_NNP federal_JJ income_NN tax_NN purposes_NNS equal_JJ to_TO the_DT difference_NN between_IN the_DT amount_NN realized_VBD and_CC such_JJ holders_NNS adjusted_VBN basis_NN in_IN the_DT Ordinary_NNP Shares_NNP or_CC ADRs_NNPS ._.
The_DT gain_NN or_CC loss_NN will_MD generally_RB be_VB US_PRP source_NN income_NN or_CC loss_NN ._.
US_NNP resident_NN shareholders_NNS should_MD consult_VB their_PRP$ own_JJ tax_NN advisors_NNS about_IN the_DT treatment_NN of_IN capital_NN gains_NNS ,_, which_WDT may_MD be_VB taxed_VBN at_IN lower_JJR rates_NNS than_IN ordinary_JJ income_NN for_IN non-corporate_JJ taxpayers_NNS and_CC capital_NN losses_NNS ,_, the_DT deductibility_NN of_IN which_WDT may_MD be_VB limited_VBN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN 152_CD Form_NN 20-F_JJ Information_NN 2004_CD Shareholder_NN Information_NN continued_VBD UK_NNP inheritance_NN tax_NN Under_IN the_DT current_JJ Double_RB Taxation_NNP Estates_NNP Convention_NNP the_DT Estate_NNP Tax_NNP Convention_NNP between_IN the_DT US_NNP and_CC the_DT UK_NNP ,_, Ordinary_NNP Shares_NNP or_CC ADRs_NNPS held_VBN by_IN an_DT individual_JJ shareholder_NN who_WP is_VBZ domiciled_VBN for_IN the_DT purposes_NNS of_IN the_DT Estate_NNP Tax_NNP Convention_NNP in_IN the_DT US_NNP ,_, and_CC is_VBZ not_RB for_IN the_DT purposes_NNS of_IN the_DT Estate_NNP Tax_NNP Convention_NNP a_DT national_JJ of_IN the_DT UK_NNP ,_, will_MD generally_RB not_RB be_VB subject_JJ to_TO UK_NNP inheritance_NN tax_NN on_IN the_DT individuals_NNS death_NN or_CC on_IN a_DT chargeable_JJ gift_NN of_IN the_DT Ordinary_NNP Shares_NNP or_CC ADRs_NNPS during_IN the_DT individuals_NNS lifetime_NN ,_, provided_VBD that_IN any_DT applicable_JJ US_NNP federal_JJ gift_NN or_CC estate_NN tax_NN liability_NN is_VBZ paid_VBN ,_, unless_IN the_DT Ordinary_NNP Shares_NNP or_CC ADRs_NNPS are_VBP part_NN of_IN the_DT business_NN property_NN of_IN a_DT permanent_JJ establishment_NN of_IN the_DT individual_NN in_IN the_DT UK_NNP or_CC ,_, in_IN the_DT case_NN of_IN a_DT shareholder_NN who_WP performs_VBZ independent_JJ personal_JJ services_NNS ,_, pertain_NN to_TO a_DT fixed_VBN base_NN situated_VBN in_IN the_DT UK_NNP ._.
Where_WRB the_DT ADRs_NNPS or_CC Ordinary_NNP Shares_NNP have_VBP been_VBN placed_VBN in_IN trust_NN by_IN a_DT settlor_NN who_WP ,_, at_IN the_DT time_NN of_IN settlement_NN ,_, was_VBD a_DT US_NNP resident_NN shareholder_NN ,_, the_DT ADRs_NNPS or_CC Ordinary_NNP Shares_NNP will_MD generally_RB not_RB be_VB subject_JJ to_TO UK_NNP inheritance_NN tax_NN unless_IN the_DT settlor_NN ,_, at_IN the_DT time_NN of_IN settlement_NN ,_, was_VBD not_RB domiciled_VBN in_IN the_DT US_NNP and_CC was_VBD a_DT UK_NNP national_JJ ._.
In_IN the_DT exceptional_JJ case_NN where_WRB the_DT Ordinary_NNP Shares_NNP or_CC ADRs_NNPS are_VBP subject_JJ both_DT to_TO UK_NNP inheritance_NN tax_NN and_CC US_NNP federal_JJ gift_NN or_CC estate_NN tax_NN ,_, the_DT Estate_NNP Tax_NNP Convention_NNP generally_RB provides_VBZ for_IN double_JJ taxation_NN to_TO be_VB relieved_VBN by_IN means_NNS of_IN credit_NN relief_NN ._.
Exchange_NNP controls_NNS and_CC other_JJ limitations_NNS affecting_VBG security_NN holders_NNS a_DT There_EX are_VBP no_DT governmental_JJ laws_NNS ,_, decrees_NNS or_CC regulations_NNS in_IN the_DT UK_NNP restricting_VBG the_DT import_NN or_CC export_NN of_IN capital_NN or_CC affecting_VBG the_DT remittance_NN of_IN dividends_NNS ,_, interest_NN or_CC other_JJ payments_NNS to_TO non-resident_JJ holders_NNS of_IN Ordinary_NNP Shares_NNP or_CC ADRs_NNPS ._.
However_RB ,_, a_DT 1.5_CD %_NN stamp_NN duty_NN reserve_NN tax_NN is_VBZ payable_JJ upon_IN the_DT deposit_NN of_IN Ordinary_NNP Shares_NNP in_IN connection_NN with_IN the_DT creation_NN of_IN ,_, but_CC not_RB subsequent_JJ dealing_NN in_IN ,_, ADRs_NNPS ._.
This_DT is_VBZ in_IN lieu_NN of_IN the_DT normal_JJ 0.5_CD %_NN stamp_NN duty_NN on_IN all_DT purchases_NNS of_IN Ordinary_NNP Shares_NNP ._.
b_NN There_EX are_VBP no_DT limitations_NNS under_IN English_JJ law_NN or_CC the_DT Companys_NNP Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP on_IN the_DT right_NN of_IN non-resident_JJ or_CC foreign_JJ owners_NNS to_TO be_VB the_DT registered_VBN holders_NNS of_IN and_CC to_TO vote_VB Ordinary_NNP Shares_NNP or_CC to_TO be_VB registered_VBN holders_NNS of_IN notes_NNS or_CC debentures_NNS of_IN Zeneca_NNP Wilmington_NNP Inc._NNP or_CC AstraZeneca_NNP PLC._NNP ._.
Exchange_NNP rates_NNS For_IN the_DT periods_NNS up_IN to_TO April_NNP 1999_CD ,_, Astra_NNP accounted_VBD for_IN and_CC reported_VBD its_PRP$ results_NNS in_IN Swedish_JJ kronor_NNS ,_, whereas_IN Zeneca_NNP accounted_VBD for_IN and_CC reported_VBD its_PRP$ results_NNS in_IN sterling_NN ._.
Consistent_JJ with_IN AstraZenecas_NNP decision_NN to_TO publish_VB its_PRP$ Financial_NNP Statements_NNP in_IN US_NNP dollars_NNS ,_, the_DT financial_JJ information_NN in_IN this_DT document_NN has_VBZ been_VBN translated_VBN from_IN kronor_NNS and_CC sterling_NN into_IN US_NNP dollars_NNS at_IN the_DT following_VBG applicable_JJ exchange_NN rates_NNS :_: SEK_NNP USD_NNP USD_NNP GBP_NNP Average_JJ rates_NNS profit_NN and_CC loss_NN account_NN ,_, cash_NN flow_NN 1995_CD 7.1100_CD 1.5796_CD 1996_CD 6.7000_CD 1.5525_CD 1997_CD 7.6225_CD 1.6386_CD 1998_CD 7.9384_CD 1.6603_CD 1999_CD 8.2189_CD 1.6247_CD End_NN of_IN year_NN spot_NN rates_NNS balance_VBP sheet_NN 1995_CD 6.6500_CD 1.5500_CD 1996_CD 6.8400_CD 1.6900_CD 1997_CD 7.8500_CD 1.6600_CD 1998_CD 8.0400_CD 1.6600_CD 1999_CD 8.5130_CD 1.6185_CD The_DT following_VBG information_NN relating_VBG to_TO average_JJ and_CC spot_NN exchange_NN rates_NNS used_VBN by_IN AstraZeneca_NNP is_VBZ provided_VBN for_IN convenience_NN :_: SEK_NNP USD_NNP USD_NNP GBP_NNP Average_JJ rates_NNS profit_NN and_CC loss_NN account_NN ,_, cash_NN flow_NN 2002_CD 9.8558_CD 1.4817_CD 2003_CD 8.3013_CD 1.6233_CD 2004_CD 7.4613_CD 1.8031_CD End_NN of_IN year_NN spot_NN rates_NNS balance_VBP sheet_NN 2002_CD 8.7700_CD 1.6093_CD 2003_CD 7.1932_CD 1.7815_CD 2004_CD 6.6144_CD 1.9264_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN Form_NN 20-F_JJ Information_NN 2004_CD 153_CD Definitions_NNS In_IN this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Information_NN the_DT following_JJ words_NNS and_CC expressions_NNS shall_MD ,_, unless_IN the_DT context_NN otherwise_RB requires_VBZ ,_, have_VBP the_DT following_VBG meanings_NNS :_: ADR_NNP American_NNP Depositary_NNP Receipt_NNP evidencing_VBG title_NN to_TO an_DT ADS_NNPS ADS_NNPS American_NNP Depositary_NNP Share_NNP representing_VBG one_CD underlying_VBG Ordinary_NNP Share_NNP Depositary_NNP JPMorgan_NNP Chase_NNP Bank_NNP ,_, as_IN depositary_NN under_IN the_DT deposit_NN agreement_NN pursuant_JJ to_TO which_WDT the_DT ADRs_NNPS are_VBP issued_VBN Directors_NNS The_DT Directors_NNS of_IN the_DT Company_NN Company_NN AstraZeneca_NNP PLC_NNP AstraZeneca_NNP ,_, AstraZeneca_NNP Group_NNP or_CC the_DT Group_NNP The_NNP Company_NNP and_CC its_PRP$ subsidiaries_NNS Ordinary_NNP Shares_NNP Ordinary_NNP Shares_NNP of_IN $_$ 0.25_CD each_DT in_IN the_DT capital_NN of_IN the_DT Company_NN LSE_NNP London_NNP Stock_NNP Exchange_NNP Limited_NNP NYSE_NNP New_NNP York_NNP Stock_NNP Exchange_NNP ,_, Inc._NNP ._.
SSE_NNP Stockholm_NNP Stock_NNP Exchange_NNP Sterling_NNP ,_, GBP_NNP ,_, pence_NN or_CC p_VB References_NNS to_TO UK_NNP currency_NN SEK_NNP ,_, kronor_NNS ,_, krona_NN References_NNS to_TO Swedish_JJ currency_NN UK_NNP United_NNP Kingdom_NNP of_IN Great_NNP Britain_NNP and_CC Northern_NNP Ireland_NNP US_NNP dollar_NN ,_, US$_$ ,_, USD_NNP or_CC $_$ References_NNPS to_TO US_NNP currency_NN US_NNP United_NNP States_NNPS of_IN America_NNP FDA_NNP Food_NNP and_CC Drug_NNP Administration_NNP of_IN the_DT US_NNP Figures_NNS in_IN parentheses_NNS in_IN tables_NNS and_CC financial_JJ statements_NNS are_VBP used_VBN to_TO represent_VB negative_JJ numbers_NNS ._.
Except_IN where_WRB otherwise_RB indicated_VBN ,_, figures_NNS included_VBD in_IN this_DT report_NN relating_VBG to_TO pharmaceutical_JJ product_NN market_NN sizes_NNS and_CC market_NN shares_NNS are_VBP obtained_VBN from_IN syndicated_VBN industry_NN sources_NNS ,_, primarily_RB IMS_NNP Health_NNP IMS_NNP ,_, a_DT market_NN research_NN firm_NN internationally_RB recognized_VBN by_IN the_DT pharmaceutical_JJ industry_NN ._.
The_DT 2004_CD market_NN share_NN figures_NNS included_VBD in_IN this_DT report_NN are_VBP based_VBN primarily_RB on_IN data_NNS obtained_VBN from_IN an_DT online_JJ IMS_NNP database_NN ._.
IMS_NNP data_NNS may_MD differ_VB from_IN that_DT compiled_VBN by_IN the_DT Group_NNP with_IN respect_NN to_TO its_PRP$ own_JJ products_NNS ._.
Of_IN particular_JJ significance_NN in_IN this_DT regard_NN are_VBP the_DT following_NN :_: 1_CD AstraZeneca_NNP publishes_VBZ its_PRP$ financial_JJ results_NNS on_IN a_DT financial_JJ year_NN and_CC quarterly_JJ interim_JJ basis_NN ,_, whereas_IN IMS_NNP issues_VBZ its_PRP$ data_NNS on_IN a_DT monthly_JJ and_CC quarterly_JJ basis_NN :_: 2_CD the_DT online_NN IMS_NNP database_NN is_VBZ updated_VBN quarterly_JJ and_CC uses_VBZ the_DT average_JJ exchange_NN rates_NNS for_IN the_DT relevant_JJ quarter_NN :_: 3_CD IMS_NNP data_NNS from_IN the_DT US_NNP is_VBZ not_RB adjusted_VBN for_IN Medicaid_NNP and_CC similar_JJ state_NN rebates_NNS :_: and_CC 4_CD IMS_NNP sales_NNS data_NNS are_VBP compiled_VBN using_VBG actual_JJ wholesaler_NN data_NNS and_CC data_NNS from_IN statistically_RB representative_JJ panels_NNS of_IN retail_JJ and_CC hospital_NN pharmacies_NNS ,_, which_WDT data_NNS are_VBP then_RB projected_VBN by_IN IMS_NNP to_TO give_VB figures_NNS for_IN national_JJ markets_NNS ._.
References_NNS to_TO prevalence_NN of_IN disease_NN have_VBP been_VBN derived_VBN from_IN a_DT variety_NN of_IN sources_NNS and_CC are_VBP not_RB intended_VBN to_TO be_VB indicative_JJ of_IN the_DT current_JJ market_NN or_CC any_DT potential_JJ market_NN for_IN AstraZenecas_NNP pharmaceutical_JJ products_NNS since_IN ,_, among_IN other_JJ things_NNS ,_, there_EX may_MD be_VB no_DT correlation_NN between_IN the_DT prevalence_NN of_IN a_DT disease_NN and_CC the_DT number_NN of_IN individuals_NNS who_WP are_VBP treated_VBN for_IN such_PDT a_DT disease_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Shareholder_NN Information_NN 154_CD Form_NN 20-F_JJ Information_NN 2004_CD Shareholder_NN Information_NN continued_VBD Terms_NNS used_VBN in_IN the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Information_NN US_NNP equivalent_JJ or_CC brief_JJ description_NN Accruals_NNP Accrued_VBN expenses_NNS Allotted_NNP Issued_NNP Bank_NNP borrowings_NNS Payable_JJ to_TO banks_NNS Called-up_JJ share_NN capital_NN Issued_VBN share_NN capital_NN Capital_NN allowances_NNS Tax_NNP term_NN equivalent_NN to_TO US_NNP tax_NN depreciation_NN allowances_NNS Creditors_NNPS Liabilities_NNPS payables_NNS Current_JJ instalments_NNS of_IN loans_NNS Long_JJ term_NN debt_NN due_JJ within_IN one_CD year_NN Debtors_NNS Receivables_NNPS and_CC prepaid_JJ expenses_NNS Earnings_NNS Net_JJ income_NN Finance_NNP lease_NN Capital_NN lease_NN Fixed_VBN asset_NN investments_NNS Non-current_JJ investments_NNS Freehold_NNP Ownership_NN with_IN absolute_JJ rights_NNS in_IN perpetuity_NN Interest_NN receivable_NN Interest_NN income_NN Interest_NN payable_JJ Interest_NN expense_NN Loans_VBZ Long_JJ term_NN debt_NN Prepayments_NNS Prepaid_JJ expenses_NNS Profit_NN Income_NNP Profit_NNP and_CC loss_NN account_NN Income_NN statement_NN consolidated_JJ statement_NN of_IN income_NN Reserves_NNS Retained_VBN earnings_NNS Short_JJ term_NN investments_NNS Redeemable_JJ securities_NNS and_CC short_JJ term_NN deposits_NNS Share_NN premium_NN account_NN Premiums_NNS paid_VBN in_IN excess_NN of_IN par_JJ value_NN of_IN Ordinary_NNP Shares_NNP Statement_NNP of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Statement_NN of_IN comprehensive_JJ income_NN Stocks_NNS Inventories_NNS Tangible_JJ fixed_VBN assets_NNS Property_NN ,_, plant_NN and_CC equipment_NN Turnover_NN Sales_NNS revenues_NNS
